eureKARE launches innovation-driven start-up studio in Monaco to apply synthetic biology in tackling critical environmental challenges Luxembourg, Belgium, and
PARIS, FRANCE / ACCESSWIRE / November 8, 2022 / Pharnext SA (FR0011191287 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative
DJ Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th